Aspirin use for the primary prevention of coronary heart disease: A population-based study in Switzerland

Preventive Medicine

Volumn 46, Issue 2, 2008, Pages 137-144

  Rodondi, Nicolas ^a   Cornuz, Jacques ^a   Marques Vidal, Pedro ^a,b   Butler, Javed ^c   Hayoz, Daniel ^a   Pécoud, Alain ^a   Paccaud, Fred ^b   Waeber, Gérard ^a   Vollenweider, Peter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c EMORY UNIVERSITY   (United States)

Author keywords

Aspirin; Coronary disease; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SWITZERLAND;

ADULT; AGED; ASPIRIN; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; SWITZERLAND;

EID: 38549111522     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2007.08.006     Document Type: Article

References (45)

1. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
2. Cabana M.D., Rand C.S., Powe N.R., Wu A.W., Wilson M.H., Abboud P.A., and Rubin H.R. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999) 1458-1465
3. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care 27 Suppl 1 (2004) S72-S73
4. Cornuz J., Gervasoni J., Hengstler P., Battegay M., and Battegay E. Prevention primaire et depistage chez l'adulte: quelles sont les priorites en 2002?. Med. Hyg. 60 (2002) 2008-2016
5. D'Agostino Sr. R.B., Grundy S., Sullivan L.M., and Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286 (2001) 180-187
6. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 10 (2003) S1-S10
7. Faragon J.J., Waite N.M., Hobson E.H., Seoldo N., Vanamburgh J.A., and Migden H. Improving aspirin prophylaxis in a primary care diabetic population. Pharmacotherapy 23 (2003) 73-79
8. Gaspoz J.M., Coxson P.G., Goldman P.A., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N. Engl. J. Med. 346 (2002) 1800-1806
9. Gostynski M., Engelter S., Papa S., Ajdacic-Gross V., Gutzwiller F., and Lyrer P. Incidence of first-ever ischemic stroke in the Canton Basle-City, Switzerland: a population-based study 2002/2003. J. Neurol. 253 (2006) 86-91
10. Grundy S.M. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation 100 (1999) 988-998
11. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
12. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998) 1755-1762
13. Hayden M., Pignone M., Phillips C., and Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 136 (2002) 161-172
14. Hedman J., Kaprio J., Poussa T., and Nieminen M.M. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int. J. Epidemiol. 28 (1999) 717-722
15. Hense H.W., Schulte H., Lowel H., Assmann G., and Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts. Eur. Heart J. 24 (2003) 937-945
16. Kim C., and Beckles G.L. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am. J. Prev. Med. 27 (2004) 1-7
17. Lauer M.S. Clinical practice. Aspirin for primary prevention of coronary events. N. Engl. J. Med. 346 (2002) 1468-1474
18. Liu J., Hong Y., D'Agostino Sr. R.B., et al. Predictive value for the Chinese population of the Framingham CHD Risk Assessment Tool compared with the Chinese Multi-provincial Cohort Study. JAMA 291 (2004) 2591-2599
19. Maciosek M.V., Coffield A.B., Edwards N.M., Flottemesch T.J., Goodman M.J., and Solberg L.I. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am. J. Prev. Med. 31 (2006) 52-61
20. Manes C., Giacci L., Sciartilli A., D'Alleva A., and De Caterina R. Aspirin overprescription in primary cardiovascular prevention. Thromb. Res. 118 (2006) 471-477
21. Marrugat J., D'Agostino R., Sullivan L., et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J. Epidemiol. Community Health 57 (2003) 634-638
22. Meigs J.B., and Stafford R.S. Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes. J. Gen. Intern. Med. 15 (2000) 220-228
23. Monesi L., Avanzini F., Barlera S., et al. Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?. Eur. J. Clin. Pharmacol. 61 (2005) 595-601
24. NCEP. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
25. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel Guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
26. Persell S.D., and Baker D.W. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch. Intern. Med. 164 (2004) 2492-2499
27. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. 296 (1988) 313-316
28. PHS. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 321 (1989) 129-135
29. Pignone M., Anderson G.K., Binns K., Tilson H.H., and Weisman S.M. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am. J. Prev. Med. 32 (2007) 403-407
30. Raine R., Streetly A., and Davis A.M. Variation in local policies and guidelines for cholesterol management: national survey. BMJ 313 (1996) 1368-1369
31. Rickenbach M., Wietlisbach V., Barazzoni F., and Gutzwiller F. Hospitalisations pour infarctus du myocarde dans les cantons de Vaud, Fribourg et Tessin: résultats de l'étude MONICA pour la période 1985-1988. Méd. Hyg. 50 (1992) 350-354
32. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352 (2005) 20-28
33. Rodondi N., and Bauer D.C. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am. J. Med. 117 (2004) 528-530
34. Rodondi N., Vittinghoff E., Cornuz J., et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am. J. Med. 118 (2005) 1288
35. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
36. SGLA. Study Group Lipids and Atherosclerosis Recommendations for the Prevention of Atherosclerosis (2005)
37. SPAF. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343 (1994) 687-691
38. Stafford R.S. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 101 (2000) 1097-1101
39. Stafford R.S., Monti V., and Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2 (2005) e353
40. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., and Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 353 (1999) 1547-1557
41. USPSTF. Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force. 2nd ed (1996), Williams & Wilkins, Baltimore
42. USPSTF. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann. Intern. Med. 136 (2002) 157-160
43. van Den Hoogen P.C., Feskens E.J., Nagelkerke N.J., Menotti A., Nissinen A., and Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N. Engl. J. Med. 342 (2000) 1-8
44. Verschuren W.M., Jacobs D.R., Bloemberg B.P., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274 (1995) 131-136
45. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847